X
Xuefeng Zhang
Researcher at Centers for Disease Control and Prevention
Publications - 37
Citations - 2437
Xuefeng Zhang is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Vaccination & Hepatitis E. The author has an hindex of 15, co-authored 32 publications receiving 2033 citations. Previous affiliations of Xuefeng Zhang include Chinese Center for Disease Control and Prevention.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
Fengcai Zhu,Jun Zhang,Xuefeng Zhang,Cheng Zhou,Zhong-Ze Wang,Shoujie Huang,Hua Wang,Chang-Lin Yang,Han-Min Jiang,Jia-Ping Cai,Yi-Jun Wang,Xing Ai,Yuemei Hu,Quan Tang,Xin Yao,Qiang Yan,Yangling Xian,Ting Wu,Yimin Li,Ji Miao,Mun-Hon Ng,James Wai-Kuo Shih,Ningshao Xia +22 more
TL;DR: HEV 239 is well tolerated and effective in the prevention of hepatitis E in the general population in China, including both men and women age 16-65 years and no vaccination-related serious adverse event was noted.
Journal ArticleDOI
Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China
Fengcai Zhu,Wenbo Xu,Jielai Xia,Zhenglun Liang,Yan Liu,Xuefeng Zhang,Xiaojuan Tan,Ling Wang,Qunying Mao,Jun-Yu Wu,Yuemei Hu,Tianjiao Ji,Li-Fei Song,Liang Qi,Baomin Zhang,Gao Qiang,Jingxin Li,Shenyu Wang,Yuansheng Hu,Shanru Gu,Jianhua Zhang,Genhong Yao,Jian-Xiang Gu,Xushan Wang,Yuchun Zhou,Changbiao Chen,Minglei Zhang,Minquan Cao,Junzhi Wang,Hua Wang,Nan Wang +30 more
TL;DR: The EV71 vaccine provided protection against EV71-associated hand, foot, and mouth disease or herpangina in infants and young children.
Journal ArticleDOI
A Novel Influenza A (H1N1) Vaccine in Various Age Groups
Fengcai Zhu,Hua Wang,Han-hua Fang,Jian Guo Yang,Xiao Jun Lin,Xiaofeng Liang,Xuefeng Zhang,Hongxing Pan,Fan-Yue Meng,Yue Mei Hu,Wen-Dong Liu,Chang-Gui Li,Wei Li,Xiang Zhang,Jin Mei Hu,Wei Bing Peng,Bao Ping Yang,Pei Xi,Hua-Qing Wang,Jingshan Zheng +19 more
TL;DR: These data suggest that a single dose of 15 microg of hemagglutinin antigen without alum adjuvant induces a typically protective immune response in the majority of subjects between 12 and 60 years of age.
Journal ArticleDOI
Long-Term Efficacy of a Hepatitis E Vaccine
Jun Zhang,Xuefeng Zhang,Shoujie Huang,Ting Wu,Yuemei Hu,Zhong-Ze Wang,Hua Wang,Han-Min Jiang,Yi-Jun Wang,Qiang Yan,Meng Guo,Xiao-Hui Liu,Jingxin Li,Chang-Lin Yang,Quan Tang,Ren-Jie Jiang,Huirong Pan,Yimin Li,J. Wai-Kuo Shih,Mun-Hon Ng,Fengcai Zhu,Ningshao Xia +21 more
TL;DR: Immunization with this hepatitis E vaccine induced antibodies against HEV and provided protection against hepatitis E for up to 4.5 years, with a vaccine efficacy of 86.8% in the modified intention-to-treat analysis.
Long-Term Efficacy of a Hepatitis E Vaccine ; 戊型肝炎疫苗的长期保护效果
Jun Zhang,夏宁邵,Xuefeng Zhang,Shoujie Huang,Ting Wu,Yuemei Hu,Zhong-Ze Wang,Hua Wang,Han-Min Jiang,Yi-Jun Wang,Qiang Yan,Meng Guo,Xiao-Hui Liu,Jingxin Li,Chang-Lin Yang,Quan Tang,Ren-Jie Jiang,Huirong Pan,Yimin Li,J. Wai Kuo Shih,J. Wai-Kuo Shih,Mun-Hon Ng,Fengcai Zhu,Ningshao Xia +23 more
TL;DR: Wang et al. as mentioned in this paper showed that vaccination with this hepatitis E vaccine induced antibodies against HEV and provided protection against hepatitis E for up to 4.5 years, while the rate of adverse events was similar in the two groups.